Background /Objective. Inadequate vitamin D (D) status is common in the very elderly yet data on dose
INTRODUCTION
There is recognition of the role of vitamin D in health and disease and the negative impact of inadequate vitamin D status. Institute of Medicine recommendations for daily vitamin D intake of 800 IU units are the same for all adults over the age of 70 years but acknowledge the paucity of data from very old people in whom physiologic, disease-related, and environmental exposure differences from younger people could affect vitamin D pharmacokinetics and pharmacodynamics. 21, [32] [33] [34] Our goal was to perform a double-blind randomized trial in the very elderly to determine steady-state circulating concentrations of total 25 (OH) vitamin D in response to vitamin D3 doses of 800 IU/day, 2000 IU/day, 4000 IU/day (tolerable upper intake level) and 50,000 IU/week used for treatment of vitamin D deficiency. We also determined steady-state relationships between total and free 25(OH)D with calcium and intact parathyroid hormone concentrations as biomarkers of vitamin D effects.
METHODS
Overall Design. A 16 week double-blind study of long-term stay nursing home residents over age 65 years randomized to D3 doses of 800, 2000, 4000 IU/day, or 50,000 IU/week.
Participants. Participants were elderly (>65 yr) clinically stable long-term stay nursing home residents (Jewish Home, San Francisco). There were no changes in medications/diagnoses within the month prior to enrollment, or hospitalizations within 6 months of enrollment. Subjects had no hypercalcemia, history of hypercalcemia, uncontrolled thyroid or parathyroid disorders, severe renal failure (estimated GFR 35 <30 ml/min/M 2 ), active malignancies (excepting non-melanoma skin cancers), intestinal bypass surgery or small bowel resection, granulomatous diseases, contraindications or allergy to D, osteoporosis or a history of fractures and receiving over 800 IU/day D, or treatment for severe D deficiency or an investigational agent in the prior six months. They received no D supplements or had stable D doses for over two months prior to entry. All were able to give informed consent or had an agent able to provide consent to the project approved by the UCSF Committee on Human Research..
Intervention . Sixteen week supplementation with 800, 2000, 4000 IU/day or 50,000 IU/week D3 was given orally. Randomization was in blocks of four stratified by sex. Nurses administered one capsule daily (D or placebo in the 50,000 IU/week group) with the meal estimated to have the highest fat intake (breakfast in 90%). Status was monitored every two weeks by interviews, and medical and nursing record reviews. Chemistry panels were analyzed at baseline, mid-study and study end. 25(OH)D and iPTH were measured at baseline and study end. Netherlands, http://www.future-diagnostics.nl/) as previously described. 36, 37 The limit of detection of the assay was 1.9 pg/mL. In the range of concentrations measured, coefficent of variation (c.v.) was < 7% .
I ntact Parathyroid Hormone (iPTH) was measured at San Francisco General Hospital Clinical laboratories, San Francisco, CA using the Siemens ADVIA Centaur® assay, a two-site sandwich immunoassay using direct chemiluminometric technology.
Adherence was calculated from capsules remaining on blister packs retrieved at 2 week intervals.
Statistical Design and Data Analysis. Demographic, clinical characteristics, and baseline characteristics of groups are presented as mean ± S. D. and compared using ANOVA.
Comparisons of concentrations in D3 dosing groups at study end were made by ANOVA.
Adherence of 80% was pre-specified for inclusion in analyses. Results presented were Bonferonni-corrected for a mid-point safety analysis. Distribution of dropout and side effects were tested by Chi square. Relationships between total and free 25(OH) D, albumin-adjusted calcium concentrations, and iPTH were tested by linear regression. In residents without a history of supplemental vitamin D, tests for time and dose effects were by repeated measures ANOVA.
ClinicalTrials.gov. The trial was registered with Clinical Trials.gov as NCT01554241.
Data and Safety
Monitoring. An NIA-appointed Data Safety and Monitoring Board monitored the study before, during, and at the termination of the study.
RESULTS
Participants. Three hundred sixty three long-term stay residents were screened of whom 277 met exclusion criteria or declined to participate. Informed consent was obtained in 86 with 4 ineligible on baseline laboratory test results and one with consent withdrawn. The study was initiated in 81 residents. Subject characteristics at baseline are presented in Table 1 . Mean
Charlson comorbidity index was 7 ± 3 and activities of daily living score was 2 ± 2 (on average, requiring assistance in 4 of 6 activities of daily living), 25 were pre-frail, 38 were frail, one was not frail using Fried criteria 38 , with frailty assessment unable to be performed in 17. Mean data are presented in Table 2 and Figure 1 and individual responses in Figure 2 . Concentrations with 50,000 IU/week were higher than all other doses, and 4000 IU day produced levels greater than .62, y=1.08 +.25*X, p<.0001) and were related to dose (see Table 2 
DISCUSSION
There are limited data on concentration responses to vitamin D in the very elderly, yet there is consensus that they are highly likely to require vitamin D supplementation because of absent or limited UVB exposure, reduced conversion of D precursor in the skin with UVB exposure, and low dietary intake of vitamin D. 34, 39, 40 Daily intake of 800 IU is the current recommendation of the IOM for people aged 70 or above based on estimates that this dose will produce or exceed a threshold of 25(OH)D of 20 ng/mL in 97.5% of people. 21 In this randomized double-blind study of elderly nursing home residents mean circulating 25(OH)D concentrations after 16 weeks of 800 IU daily were 33 ng/mL. The data support the IOM premise that most older people will achieve levels over 20 ng/mL with 800 IU/day of a formulation with documented content based on studies of somewhat younger populations. with doses over 3200 IU/day D3, although doses over 4800 IU/day were not part of the data for the model. 42 The lack of a plateau in the D3 dose vs. 25(OH)D response with doses from 1000-10,000 IU daily has previously been demonstrated in young men who achieved 25(OH)D levels of about 30, 60, and 84 ng/mL after single oral doses of 1000, 5000, and 10000 IU D3 per day. 45 These data demonstrate similar responses to supplemental oral D3 across the adult agespan and between races.
The results with dosing of 50,000 IU/wk were somewhat unexpected. Retrospective studies of responses to 50,000 IU/wk D2 for clinical vitamin D deficiency report mean 25(OH)D concentrations of about 33 ng/mL after at least 60 days 46 or three to 12 months. 47 In the current study, mean 25(OH)D concentrations were 61 ng/mL with levels over 40 ng/ml in all receiving 50,000 IU D3 weekly and exceeded 50 ng/mL in over half. Potential explanations for the differences include greater adherence in this prospective study compared to retrospective studies and that D3 and D2 differ in pharmacokinetics and pharmacodynamics. [48] [49] [50] [51] [52] Most, but not all, of the literature suggests that lower total 25(OH)D concentrations are reached with D2 compared to D3, 48, 49, 53, 54 including a single-blind direct comparison with 50,000 IU/week in healthy middleaged people. 55 This may be clinically important as 50 000 IU D3 formulations are commercially available, and results with 50000 IU D3 weekly may differ from dosing with the prescription dose of 50,000 IU D2. 56 In this study, the lowest free 25(OH)D levels were seen in the 800 IU/day group giving further support to a potential need for doses over 800 IU/day in some elderly, although all free 25(OH)D levels were within the range we have seen in healthy people. Conversely, free 25(OH)D levels in some participants receiving 4000 IU/day and in all receiving 50,000 IU D3/wk exceeded levels seen in healthy subjects, stable patients, and even cirrhotics. The implications are uncertain but warrant further investigation.
Potential Limitations. The 16 week duration was based on prior investigations showing a three to four month duration of D3 dosing to reach steady-state in adults of younger to middle age. 45 48, 54, 57 We found small increases in 25(OH)D from 8 to 16 weeks with 4000 IU/day and 50000/wk in D supplement naive participants (p=.035 with Bonferroni Dunn criteria for significance of p <.0167). There may have been a small underestimation of peak steady-state concentrations for these doses in D naïve people. Sample sizes were relatively small (about 20 per group), but the same or larger than other D dose ranging studies. 42, 43, 48, 53, 54 We studied nursing home residents but note that due to lack of financial assistance for assisted living, board and care, or retirement facilities in California , many participants were of similar age and health status to older people who have limited sunshine exposure living in the community in other states. Finally, concentration responses to vitamin D3 doses have been reported to be the same in blacks as whites 43 but we studied only whites and cannot address potential racial differences. 
